{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
Basel, 1 November 2005\line \line {\b Roche and Protein Design 
Labs to jointly 
develop daclizumab in transplant maintenance therapy} \line \line Roche and 
Protein 
Design Labs, Inc. (PDL) (NASDAQ: PDLI) today announced an expansion to their partnership to co-develop 
and commercialize daclizumab for organ transplant patients on long-term, maintenance therapy. Roche 
currently markets daclizumab for induction transplant therapy as Zenapax. Roche and PDL are developing 
a new subcutaneous daclizumab (daclizumab s.c.) formulation, manufactured by PDL, for use in Phase II 
clinical trials expected to start in 2006.\line \line Currently, transplant patients 
are treated with the combination therapy of Roche\u8217?s CellCept (mycophenolate mofetil) with a calcineurin 
inhibitor such as cyclosporine and steroids to prevent organ rejection. However, the long-term use of 
the current calcineurin inhibitors can cause kidney toxicity, diabetes and cardiovascular disorders. 
Using daclizumab s.c. as maintenance treatment in combination with CellCept may allow for the reduction, 
and potential elimination, of the more toxic drugs from transplant patient maintenance regimens.\line \line Mark 
McDade, Chief Executive Officer, PDL, said, \u8220?We are enthusiastic about the opportunity to develop daclizumab 
s.c. with our longstanding partner Roche. Today\u8217?s agreement builds upon our existing collaboration with 
Roche in asthma, as we continue to explore development of daclizumab s.c. in other indications.\u8221?\line \line \u8220?Roche 
and PDL are highly committed to daclizumab, our partnership, and in developing better treatments to 
improve long-term outcomes for transplant patients,\u8221? said Peter Hug, Roche\u8217?s Global Head of Pharma Partnering. 
\u8220?With the potential to use CellCept and daclizumab s.c. as the centerpiece for long-term transplant 
therapy, we could offer patients a safer, more tolerable option.\u8221?\line Roche and PDL have 
amended their current agreements to reflect the scope of daclizumab s.c.\u8217?s further development. Under 
the terms of this agreement, PDL will receive a $10 million upfront payment and may be eligible to receive 
payments up to $145 million if certain milestones are satisfied and if the indication is successfully 
developed. Roche will continue to manufacture and promote Zenapax exclusively on a worldwide basis. 
Roche and PDL will share equally global development costs, and PDL has the option to co-promote daclizumab 
s.c. for transplant maintenance in the United States. Outside the United States, PDL will receive royalties 
on net sales of the product in transplant maintenance. As part of this arrangement, the parties agree 
that PDL will not exercise its option to promote Zenapax for prevention of acute kidney transplant rejection 
and PDL is no longer required to make the payment which would otherwise be due in 2007 for such right. 
PDL and Roche will continue with the co-development of daclizumab s.c. in respiratory disorders, as 
announced in September 2004.\line \line {\b About the Roche - PDL partnership} \line In 
1989, Roche acquired the worldwide rights to daclizumab, a product approved in 1997 as Zenapax for the 
prevention of renal allograft rejection. In October 2003, Roche returned to PDL all rights to daclizumab, 
except in transplantation where PDL retained the option until 2007 to re-acquire development rights. 
In September 2004, PDL and Roche announced the continued co-development of daclizumab s.c. in respiratory 
disorders.\line \line {\b Roche in Transplantation} \line Roche 
is strongly 
committed to improving the long-term outcomes of transplantation and enhancing the quality of life of 
transplant recipients. Roche has developed innovative therapies that improve graft and post-transplant 
health. CellCept is the cornerstone of current immunosuppressant therapies for transplant recipients 
and is the largest selling branded immunosuppressive in North America. Zenapax prevents acute rejection 
of the newly transplanted organ. Valcyte (valganciclovir) was developed for the prevention of cytomegalovirus, 
a dangerous viral infection associated with transplantation. In addition, Roche supports basic research 
in transplantation with its funding of the independent Roche Organ Transplantation Research Fund (ROTRF), 
which directly supports innovative research projects attracting new researchers with innovative and 
novel scientific ideas to meet unmet medical needs in solid organ transplantation.\line \line {\b About 
Protein Design Labs} \line PDL is a biopharmaceutical company focused on the research, 
development 
and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions 
and cancer. PDL markets several products in the United States through its hospital sales force and wholly-owned 
subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed 
its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties 
on net sales of licensed products. Further information on PDL is available at www.pdl.com (http://www.pdl.com).\line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused 
healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products 
and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes 
on a broad range of fronts to improving people\u8217?s health and quality of life. Roche is a world leader 
in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader 
in virology. In 2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss francs, while 
the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people 
in 150 countries and has R&D agreements and strategic alliances with numerous partners, including 
majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is 
available on the Internet (www.roche.com (http://www.roche.com)).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are legally protected.\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}